Crenigacestat
As of the edition of 20 October 2026, Crenigacestat is a small molecule: stopped in 2025; acts on NOTCH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 9, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Digestive system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Crenigacestat.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NOTCH1 | Neurogenic locus notch homolog protein 1 | P46531 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 5 | 0 | 3 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2012 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2021 to now |